

General Information

EudraVigilance Local Report Number	EU-EC-10010010062
Sender Type	Regulatory authority
Sender's Organisation	EEA Regulator
Type of Report	Spontaneous
Primary source country	Non-European Economic Area
Reporter's qualification	Healthcare Professional
Case serious?	Yes

Patient

Age Group	Age Group (as per reporter)	Sex
12-17 Years		Female

Reaction / Event

MedDRA LLT	Duration	Outcome	Seriousness <sup>1</sup>
Stroke	1.0 Days	Fatal	death.

Drug Information

Role <sup>2</sup>	Drug	Duration	Dose	Units in Interval	Action taken
S	COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) - COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)	1.0 Days			Not applicable

Drug Information (cont.)

Info <sup>3</sup>	Drug	Indication	Pharm. Form	Route of Admin.
	COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) - COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)	N/A		Intramuscular use

1

Seriousness: **death**=results in death; **life threat.**=life threatening; **hospital.**=requires hospitalization/prolongation of hospitalization; **disability**=results in disability/incapacity; **congen.**=congenital anomaly/birth defect; **other**=other medically important information; **(blank)**=non-serious

2

Drug role: **S**=suspect; **C**=concomitant; **I**=interacting; **N**=not administered

3

Additional Information on Drug: **1**=Counterfeit; **2**= Overdose; **3**=Drug taken by the father; **4**=Drug taken beyond expiry date; **5**=Batch and lot tested and found within specifications; **6**=Batch and lot tested and found not within specifications; **7**=Medication error; **8**=Misuse; **9**=Abuse; **10**=Occupational exposure; **11**=Off label use; **(blank)** =no additional information

Report generated: 19/05/2024 02:36:05

Page 1 of 1